The purpose of this study is to examine regorafenib in patients with different types of sarcoma, a kind of cancer that affects the body's connective tissues. This study investigates how regorafenib, which is part of a group of drugs called small molecule oral kinase inhibitors (SMOKIs), works in sarcomas other than gastrointestinal stromal tumors (GIST). These inhibitors block certain proteins that help cancer cells grow, and this study aims to understand their effects on sarcomas.

Participants in this study will take regorafenib orally. Regorafenib works by inhibiting certain proteins that are involved in cancer cell growth. This study will look at its impact on sarcoma tumors, including liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma. Participants will not receive any payment for their involvement in the study.

• Who can participate: Adults with advanced or metastatic liposarcoma, osteogenic sarcoma, or Ewing/Ewing-like sarcoma are eligible. Participants must have had at least one prior systemic therapy and be able to swallow oral medication. Adequate organ function is required. Exclusion criteria include no prior SMOKI treatment and no recent major surgery.
• Study details: Participants will take regorafenib, an investigational medication that blocks certain proteins in cancer cells. The study involves taking this medication orally to assess its effects on sarcoma tumors.